Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05750355
Other study ID # TPN171H-11
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 10, 2022
Est. completion date December 7, 2022

Study information

Verified date April 2023
Source Vigonvita Life Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-dose orally administered, dose-escalation, single-center, randomized, double-blind, placebo-parallel controlled clinical study evaluating the effect of TPN171H tablets on QT/QTc interval in healthy subjects.The main objective was to evaluate the effect of TPN171H tablets on QT/QTc interval in healthy Chinese subjects after a single oral administration.


Description:

This trial was a single-center, randomized, double-blind, placebo parallel controlled trial of TPN171H tablets with single oral administration, dose escalation, in healthy Chinese subjects. This trial plans to set up 4 dose groups, and a total of 32 healthy adult subjects are expected to be enrolled. All subjects will receive a single oral dose under fasting state, and complete 3 days of PK blood sampling, 12-lead ECG examination and other safety checks. The trial was sequential according to the principle of dose escalation, that is, the next dose group was tested on the premise that the safety and tolerability of the previous group were good.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 7, 2022
Est. primary completion date December 7, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Age 18-45 years old, both male and female; 2. Weight: male = 50 kg, female = 45 kg, 19 kg/m2 = BMI =26 kg/m2 3. Three 12-lead ECG examinations (the average of three measurements will be used to determine eligibility), QTcF=450 ms, PR interval =200 ms, and QRS duration <120 ms; 4. Reliable contraceptive measures will be taken from the signing of the informed consent to 3 months after the medication, and there is no plan to donate sperm or eggs. The specific contraceptive measures are detailed in the appendix. 5. Able to understand the procedures and methods of this trial, willing to strictly abide by the clinical trial protocol to complete this trial, and voluntarily sign the informed consent. Exclusion Criteria: 1. Known allergic history to the investigational drug and any of its components or related preparations; 2. People with allergic diseases, food allergies or allergic constitutions; 3. have a history of risk factors for torsdos de pointes, or have a family history of short QT syndrome, long QT syndrome, unexplained sudden death in young adulthood (=40 years old), drowning or sudden infant death syndrome in first-degree relatives (i.e., biological parents, siblings or children); 4. Previous history of hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia; 5. Those who have definite diseases of the central nervous system, cardiovascular system, digestive system (including those with moderate or severe fatty liver on B-ultrasound examination), respiratory system, urinary system, blood system, and metabolic disorders that require medical intervention or other diseases that are not suitable for clinical trials (such as psychiatric history, etc.); 6. Patients with blurred vision or history of ophthalmology (such as abnormal color vision, retinitis pigmentosa, macular degeneration); 7. Patients with a history of postural hypotension; 8. Patients with a history of acute respiratory infection or acute illness within 14 days before screening; 9. Those who had donated blood or lost =400 mL of blood within 3 months before screening; 10. Use of any drugs that inhibit or induce liver metabolism of drugs (such as: inducers - barbiturates, carbazepine, phenytoin, glucocorticoids, omeprazole; Inhibitors -SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazole, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines); 11. Those who have taken any prescription drugs, non-prescription drugs, health care products, vitamins and Chinese herbal medicines within 14 days before screening; 12. Consuming grapefruit, grapefruit, pitaya, mango and other fruits or related products that affect metabolic enzymes within 7 days before screening; 13. Intake of caffeine-rich or xanthine-rich beverages or foods (such as coffee, strong tea, chocolate, cola, etc.) within 48 h before screening; 14. Those who participated in other drug clinical trials within 3 months before screening; 15. Current or former drug users or alcohol addicts, current or former alcoholics (drinking more than 14 standard units per week). 1 standard unit containing 14g of alcohol (e.g. 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or a positive breath test for alcohol; 16. Those who smoked more than 10 cigarettes per day in the previous 3 months were screened; 17. Physical examination, abnormal vital signs (ear temperature >37.5?, respiratory rate >20 beats/minute, pulse rate >100 beats/minute, systolic blood pressure =140 mmHg or <90 mmHg, diastolic blood pressure =90 mmHg or <50 mmHg), abnormal and clinically significant laboratory results, and those who have an impact on the evaluation of this trial; 18. Laboratory tests showed that serum potassium, magnesium and calcium were beyond the normal range and the abnormalities were judged by the researchers to be clinically significant; 19. Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, syphilis antibody (TPPA) or human immunodeficiency virus (HIV) antibody positive; 20. Abnormal chest X-ray (anteroposterior and lateral view) or lung CT results with clinical significance; 21. Women with positive blood pregnancy test (applicable to women) or lactating women; 22. Those who have other factors that the investigator considers unsuitable for participation in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TPN171H 10 mg Group
6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 30 mg Group
6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 40 mg Group
6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
TPN171H 50 mg Group
6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.

Locations

Country Name City State
China Huashan Hospital affiliated to Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Vigonvita Life Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary QT Interval Corrected Using Fridericia's Formula Model-guided placebo-corrected change in QTcF from baseline (??QTcF) From Day 1 to Day3
Secondary QT Interval Change in QT interval from baseline From Day 1 to Day3
Secondary Corrected QT interval Change in QTc interval from baseline From Day 1 to Day3
Secondary PR interval Change in PR interval from baseline From Day 1 to Day3
Secondary RR interval Change in RR interval from baseline From Day 1 to Day3
Secondary QRS duration Change in QRS duration limit interval from baseline From Day 1 to Day3
Secondary Heart rate Change in HR from baseline From Day 1 to Day3
Secondary T-wave Whether the T-wave shape is abnormal From Day 1 to Day3
Secondary U-wave Whether the U-wave shape is abnormal From Day 1 to Day3
Secondary Number of participants with arrhythmic Number of participants with arrhythmic, arrhythmic includes Atrial fibrillation, atrial flutter, atrioventricular block, ST segment changes, etc From Day 1 to Day3
Secondary Tmax time to peak From Day 1 to Day3
Secondary Cmax maximum concentration From Day 1 to Day3
Secondary plasma half-life(T1/2) Elimination half life From Day 1 to Day3
Secondary Area under concentration-time curve (AUC0-t) Area under concentration-time curve (AUC0-t) From Day 1 to Day3
Secondary Incidence of adverse events Incidence of adverse events From Day 1 to Day3
Secondary Severity of adverse events Severity of adverse events From Day 1 to Day3
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1